All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VET2-L2
Therapeutic Area: Oncology Product Name: VET2-L2
Highest Development Status: Preclinical Product Type: Large molecule
Recipient: KaliVir Immunotherapeutics
Deal Size: $634.0 million Upfront Cash: $56.0 million
Deal Type: Licensing Agreement December 07, 2020
Details:
Under the terms of the agreement, Astellas will pay to KaliVir up to US$56 million in the form of an upfront payment and other payments to support research and preclinical activities related to VET2-L2 and the Second Product.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Roxadustat
Therapeutic Area: Hematology Product Name: Evrenzo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: FibroGen, Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2020
Details:
The MHLW approval of EVRENZO marks the second approval in Japan for roxadustat through the Astellas and FibroGen collaboration, after the therapy was approved and launched for use in adult patients with anemia of CKD on dialysis last year.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gilteritinib
Therapeutic Area: Oncology Product Name: Xospata
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Oral presentations include new data on the use of gilteritinib, either as monotherapy or in combination, across the FLT3mut+ AML patient spectrum – from those newly diagnosed, to relapsed or refractory patients who have been pre-treated with other tyrosine kinase inhibitors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Details:
The approval is based on results from the PROSPER trial, a double-blind, placebo-controlled, pivotal Phase 3 trial that evaluated enzalutamide plus ADT versus placebo plus ADT in 1,401 men with nmCRPC and rapidly rising prostate-specific antigen levels.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ASP0367
Therapeutic Area: Genetic Disease Product Name: MA-0211
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
Preclinical data and results from Astellas’ Phase I healthy volunteer study collectively suggest that ASP0367 could improve exercise intolerance and fatigue in PMM patients by increasing the number and enhancing the function of mitochondria in patient’s cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Roxadustat
Therapeutic Area: Hematology Product Name: ASP1517
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: FibroGen, Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
Abstracts include presentations of the Phase 3 DOLOMITES study and a Japanese Phase 3 CL-0310 study, with both studies evaluating roxadustat versus darbepoetin alfa as a treatment for patients with anemia of CKD not on dialysis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Enfortumab vedotin-ejfv
Therapeutic Area: Oncology Product Name: Padcev
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The cohort is evaluating the antibody-drug conjugate PADCEV® for patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor and have not received a platinum-containing chemotherapy and are ineligible for cisplatin.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV-based gene therapy
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Recipient: The University of Pittsburgh School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 24, 2020
Details:
Cell Biology and Developmental Biology in University of Pittsburgh School of Medicine and Astellas will work jointly to evaluate and optimize the drug candidates with an aim to provide new treatment options to help recover and maintain vision in dry AMD patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ASP8062
Therapeutic Area: Psychiatry/Psychology Product Name: ASP8062
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 22, 2020
Details:
Should the phase 1 studies demonstrate appropriate safety measures, a second phase of the grant may be awarded to help fund a randomized double-blind phase 2 study to assess the safety and efficacy of ASP8062 on the reduction of opioid use in OUD patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Enfortumab vedotin-ejfv
Therapeutic Area: Oncology Product Name: Padcev
Highest Development Status: Approved Product Type: Large molecule
Recipient: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
The global EV-301 clinical trial compared PADCEV to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
